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Summary
Purpose:  The  objective  of  this  study  was  to  describe  the  epidemiological  charac-
teristics,  clinical  features,  treatment,  and  outcome  of  2009  H1N1-infected  patients
who  were  admitted  to  the  intensive  care  unit  (ICU)  at  King  Saud  Medical  City  (KSMC)
in  Riyadh,  Kingdom  of  Saudi  Arabia.
Methods:  Retrospectively,  we  collected  demographic  data  as  well  as  data  on  the
clinical  presentation  and  risk  factors  for  86  patients  who  were  admitted  to  the  ICU
with  H1N1  inﬂuenza  A.  The  APACHE  IV  System  was  used  to  assess  the  severity  of  the
illness.  The  overall  hospital  mortality  was  calculated  and  correlated  with  the  use  of
steroids  and  the  time  of  oseltamivir  administration.
Results:  The  mean  age  of  the  patients  was  40.8  years.  Mortality  increased  steadily
with  increasing  APACHE  IV  score.  Patients  who  received  steroids  had  a  mortality
rate  of  47%  compared  with  23%  for  patients  who  were  not  treated  with  steroids;  this
difference  was  signiﬁcant,  with  a  P  value  of  <0.01.
The  late  administration  of  oseltamivir  was  associated  with  a  mortality  rate  of  82%
compared  with  28%  in  the  context  of  early  oseltamivir  administration;  this  difference
was  signiﬁcant,  with  a  P  value  of  <0.01.
Conclusions:  Patients  who  were  admitted  to  the  ICU  with  severe  2009  H1N1  infection
were  young  and  had  a  relatively  high  severity-of-illness  score.  The  late  administra-
tion  of  oseltamivir  was  associated  with  a  12-fold  increase  in  mortality.  Steroid  use
3-folwas  associated  with  a  
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n  April  21,  2009,  the  Centers  for  Disease  Con-
rol and  Prevention  reported  the  detection  of  2
ases of  human  infection  with  2009  inﬂuenza  A
H1N1) in  California  [1],  and  on  June  11,  2009,  the
orld Health  Organization  formally  conﬁrmed  the
rst pandemic  of  inﬂuenza  in  40  years  [2].  Subse-
uently,  infection  with  this  virus  has  been  reported
n virtually  every  country  [3—6].  The  novel  pan-
emic  A/H1N1  virus,  which  contains  swine,  avian,
nd human  elements  [2],  began  to  cause  illness
n Saudi  Arabia  approximately  two  months  after
t ﬁrst  emerged  in  Mexico.  The  ﬁrst  case  was
eported in  Riyadh,  Saudi  Arabia,  on  June  3,  2009.
he greatest  burden  of  critical  illness  and  death
ccurred  in  Saudi  Arabia  between  July  1,  2009,
nd February  28,  2010.  The  objective  of  this  study
as to  describe  the  epidemiological  characteris-
ics, clinical  features,  treatment,  and  outcome  of
atients with  severe  cases  of  2009  H1N1  inﬂuenza  A
nfections who  were  admitted  to  the  intensive  care
nit (ICU)  at  King  Saud  Medical  Complex  (KSMC)  in
iyadh, Kingdom  of  Saudi  Arabia.
ethods
etrospectively,  we  collected  data  on  the  demo-
raphics,  clinical  presentation,  risk  factors  and
anagement  for  all  patients  who  were  admitted
o the  ICU  at  KSMC  with  a  conﬁrmed  diagnosis
f severe  2009  H1N1  inﬂuenza  A  with  respiratory
ailure. The  2009  H1N1  inﬂuenza  strain  was  identi-
ed by  real-time  reverse  transcription  polymerase
hain reaction  (RT-PCR)  analysis  of  upper  respi-
atory  tract  (nasopharyngeal)  or  lower  respiratory
ract  (endotracheal)  specimens.  The  data  collected
ncluded  the  dates  of  admission  to  the  hospital
nd ICU;  age;  sex;  pregnancy  or  childbirth  less
han 28  days  prior  (for  women);  coexisting  con-
itions,  which  were  deﬁned  as  immunodeﬁciency,
ystic ﬁbrosis,  congenital  heart  disease,  neuromus-
ular  disorder,  or  chronic  neurological  impairment;
istory of  asthma  or  another  chronic  pulmonary
isease, chronic  heart  failure,  or  diabetes;  esti-
ated weight  and  height  (for  calculation  of  the
ody mass  index  [BMI]);  date  of  the  ﬁrst  symptoms;
resence  and  type  of  inﬂuenza  syndrome,  includ-
ng viral  pneumonitis  or  acute  respiratory  distress
yndrome,  secondary  bacterial  pneumonia,  exacer-
ation of  airﬂow  limitations  due  to  either  asthma
r chronic  obstructive  pulmonary  disease,  or  inter-
urrent  illness;  and  airway  status  at  the  time  of
CU admission  (presence  or  absence  of  endotra-
heal intubation,  tracheotomy,  sealed  face  mask,
a
p
eigure  1  Epidemiologic  curve  of  ICU  admitted  cases  of
andemic  2009  inﬂuenza  A.
r  any  artiﬁcial  airway).  We  categorized  patients
ccording to  the  age  groups  used  in  a previous
eport: 5—24  years,  25—49  years,  50—64  years,
nd 65  years  of  age  or  older.  We  calculated  the
uration  of  treatment  in  the  ICU  and  the  hospital.
he Acute  Physiology  and  Chronic  Health  Evaluation
APACHE)  IV  system  was  used  to  assess  the  severity
f the  illness  within  the  ﬁrst  24  h  after  admis-
ion. The  outcomes  were  overall  hospital  mortality
nd mortality  based  on  the  use  of  steroids  and
n the  time  of  administration  of  oseltamivir  treat-
ent. Patients  were  stratiﬁed  based  on  the  use
f steroids  (1  mg/kg  methylprednisolone  per  day
or early  phase  ARDS,  continued  for  7  days)  and
he early  administration  of  oseltamivir  treatment
within  the  ﬁrst  48  h of  presentation).  The  mortal-
ty rates  of  the  stratiﬁed  groups  were  compared,
nd P  values  using  the  chi-squared  test  and  odds
atios with  95%  CI  were  calculated  for  the  results.
esults
uring  the  ﬁrst  wave  of  the  2009  H1N1  pandemic,  a
otal of  86  patients  that  ﬁt  our  criteria  were  admit-
ed to  the  intensive  care  unit  between  July  1  and
ebruary  28,  2010  (Fig.  1).  Seventy-two  percent  of
he patients  were  male,  and  28%  were  female.
The mean  age  was  40.8  years,  and  the  number
f admissions  varied  substantially  according  to  the
ge group.  The  highest  number  of  ICU  admissions
as among  patients  25—49  years  of  age  (Fig.  2).
Additional demographic  data  and  data  on  risk
actors  and  the  type  of  critical  illness  among
atients with  2009  H1N1  inﬂuenza  are  presented
n Table  1.A total  of  8  of  the  86  patients  (9%)  who  were
dmitted to  the  ICU  with  2009  H1N1  inﬂuenza  were
regnant  women,  29  patients  (33.7%)  were  smok-
rs, 19  (22.1%)  were  hypertensive,  21  (26.3%)  were
54  A.  Mady  et  al.
Table  1  Baseline  characteristics  of  patients  with  conﬁrmed  critical  illness  related  to  2009  H1N1  inﬂuenza.a
Characteristic  Value
Age-Yr
Mean  40.8
IQR  29—51
Female  sex—–no./total  no.  (%)  22/86  (28)
Pregnant—–no./total  no.  (%) 8/86 (9)
Race  or  ethnic  group—–no./total  no.  (%)
White 67/86  (63.9)
Indian  or  Pakistani 16/86  (18.6)
African  3/86  (3.5)
Smoking—–no./total  no.  (%)  29/86  (33.7)
Hypertension—–no./total  no.  (%)  19/86  (22.1)
Diabetes—–no./total  no.  (%) 21/86 (26.3)
Asthma  or  chronic  pulmonary  disease—–no./total  no.  (%)  33/86  (38.3)
Adults  with  BMI  >25—–no./total  no.  (%)b 12/86  (14)
No  known  predisposing  factors—–no./total  no.  (%)  11/86  (12.8)
Time  from  ﬁrst  symptoms  to  hospital  admission—–days
Median  3
IQR  3—5
Inﬂuenza  syndrome—–no./total  no.  (%)
Respiratory  failure 69/86 (86.3%)
Viral  pneumonitis  10/86  (12.5)
Secondary  bacterial  pneumonia  34/86  (42.5)
Exacerbation  of  airﬂow  limitation 12/86  (15)
Severity  of  illness  assessment  at  ICU  admission
APACHE  IV:  average  (IQR) 105.6 (41—190)
a ARDS denotes the acute respiratory distress syndrome, ICU intensive care unit, and IQR interquartile range.
b The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
diabetic,  12  (14%)  had  a  BMI  of  greater  than  25,  33
(38.3%) had  asthma  or  another  chronic  pulmonary
disease and  11  (12.8%)  had  no  predisposing  factors.
The median  APACHE  IV  score  was  105.6  with  an  IQR
of 41—190.
The  median  duration  from  the  start  of  symp-
toms until  hospital  admission  was  3  days,  with
an interquartile  range  of  3—5  days  and  a  median
time from  hospitalization  to  ICU  admission  of  1
day. Sixty-nine  patients  (86.3)  were  admitted  to
Figure  2  Number  of  admissions  to  the  intensive  care
unit  (ICU),  according  to  age  group.
the  ICU  with  a diagnosis  of  respiratory  failure,  10
patients (12.5%)  had  viral  pneumonitis,  34  patients
(42.5) had  secondary  bacterial  pneumonia  (i.e.,
unilateral  or  bilateral  asymmetric  lung  inﬁltrates
consistent with  bacterial  pneumonia,  with  bacte-
rial infection  proven  or  suspected),  and  12  patients
(15%) exhibited  the  exacerbation  of  airﬂow  disease,
such as  asthma  or  COPD.  Eighty-one  percent  were
mechanically  ventilated,  with  an  average  duration
of mechanical  ventilation  of  7.5  days  and  an  aver-
age ICU  length  of  stay  of  8  days.
The different  rescue  therapies  that  were  used  in
those patients  are  summarized  in  Table  2.
Acute renal  failure  occurred  in  24  patients
(24.4%), pneumothorax  in  4  patients  (4.7%),  rhab-
domyolysis  in  5  patients  (5.8%),  suspected  or
Table  2  Rescue  therapies  used  in  2009  H1N1  cases.
Rescue  therapy  Value
Airway  pressure  release  ventilation  42/86  (49%)
High  frequency  ventilation  18/86  (26%)
Prone  position  12/86  (14%)
Nitric  oxide  therapy  6/86  (7%)
Paralytic  agent  37/86  (43%)
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onﬁrmed  pulmonary  embolism  in  6  patients  (7%),
nd myocarditis  in  4  patients  (4.7%).
The  mortality  rate  increased  steadily  with
ncreasing severity  of  illness,  with  an  overall  mor-
ality rate  of  35%  for  a  mean  APACHE  IV  score  of
05.6.  The  mortality  rate  was  19%  for  the  APACHE
V group  with  scores  of  40—90,  33%  for  the  group
ith scores  of  91—140  and  73%  for  the  group  with
cores  of  141—190  (P  value  <0.01  among  all  groups)
Fig. 3).  The  rate  of  mortality  among  pregnant
omen was  33%.
Fifty  percent  of  patients  received  steroid  ther-
py and  had  a  mortality  rate  of  47%  compared  with
3% for  those  who  did  not  receive  steroid  therapy;
his difference  was  signiﬁcant,  with  a  P  value  of
0.01 and  an  odds  ratio  (OR)  of  2.87  (95%  conﬁdence
nterval  (CI):  1.14—7.25).  There  was  no  statistically
igniﬁcant difference  between  the  average  APACHE
V scores  of  the  two  groups  (110.5  vs.  100.6,  P  value
0.05) (Fig.  4).
The  late  administration  of  oseltamivir  (>48  h
fter the  initial  presentation)  was  associated  with
n overall  mortality  of  82%  compared  with  28%
or those  who  received  early  administration  of
seltamivir  therapy;  this  difference  was  signiﬁcant,
ith  a  P  value  of  <0.01  and  an  OR  of  11.6  (95%  CI:
.3—58) (Fig.  5).
igure  4  Mortality  rates  associated  with  steroid  use.
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arly  oseltamivir  use.
iscussion
evere  cases  of  the  winter  outbreak  of  2009
nﬂuenza A  (H1N1)  infection  in  Saudi  Arabia  were
ost common  among  young  males,  with  a  mortality
ate of  35%  among  critically  ill  patients  compared
ith 41.4%  in  Mexico  [7],  17.3%  in  Canada  [8],  14%
n Australia  and  New  Zealand  [9]  and  28%  in  the  USA
10]. A  history  of  lung  disease  or  smoking,  hyperten-
ion,  diabetes  and  obesity  were  the  most  common
omorbidities;  only  12.8%  of  patients  had  no  predis-
osing risk  factor.  Critical  illness  occurred  rapidly
fter hospital  admission  and  was  associated  with
evere oxygenation  failure,  a  requirement  for  pro-
onged mechanical  ventilation,  and  the  frequent
se of  rescue  therapies.
The  early  Mexican  experience  study  [11]  sug-
ested that  the  use  of  steroids  may  increase  the
isk of  death  by  approximately  3-fold,  with  an  odds
atio of  3.37  (95%  CI:  0.25—52.34),  but  due  to  the
ow number  of  patients,  the  P  value  was  0.32.  In
ur study,  with  a  total  of  43  patients  who  received
teroids  during  hospitalization  compared  with  43
atients who  did  not  receive  steroid  therapy,  the
isk of  death  increased  by  2.87,  with  a P  value  of
tatistical  signiﬁcance  and  a  95%  CI  of  1.14—7.25.
These ﬁndings  are  similar  to  those  for  steroid
herapy in  the  treatment  of  avian  inﬂuenza  [12],  for
hich the  mortality  rate  was  higher  when  steroids
ere  used.  It  is  hypothesized  that  steroids  may
lay a role  in  increasing  replication  of  the  virus  in
he respiratory  endothelium  and  thus  increasing  the
everity of  illness  and  mortality,  but  there  are  no
ata to  conﬁrm  this  hypothesis.
It has  been  noted  that  the  initiation  of
seltamivir therapy  within  the  ﬁrst  12  h  after
he onset  of  fever  in  seasonal  inﬂuenza  patients
educed the  duration  of fever,  the  severity  of  symp-
oms and  the  time  to  return  to  baseline  activity  and
ealth scores  [13].  It  has  been  recommended  that
[[
[
[
[56  
oseltamivir  therapy  should  be  started  as  early  as
possible in  patients  with  seasonal  inﬂuenza  [14].
In our  study,  patients  for  whom  treatment  with
oseltamivir  was  delayed  had  a  risk  of  death  that
was increased  by  12-fold  compared  with  that  the
risk in  patients  who  received  oseltamivir  therapy
within  the  ﬁrst  48  h  of  illness.
We  conclude  that  patients  who  were  admitted  to
the ICU  with  severe  2009  H1N1  infection  were  young
and had  a  relatively  high  severity  of  illness.  The
most common  risk  factors  were  bronchial  asthma
and obesity;  pregnancy  was  also  considered  a  risk
factor. The  overall  hospital  mortality  was  35%.  The
late administration  of  oseltamivir  was  associated
with a  12-fold  increase  in  mortality,  and  steroid  use
was associated  with  a  3-fold  increase  in  mortality.
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